Nanobioprinting Technologies in 2025: Unleashing the Next Wave of Precision Biofabrication. Explore How Cutting-Edge Advances Are Shaping Healthcare, Research, and Industry for the Next Five Years.

• Executive Summary: Key Trends and Market Outlook (2025–2030)
• Technology Landscape: Core Principles and Innovations in Nanobioprinting
• Market Size, Growth Drivers, and Forecasts Through 2030
• Leading Players and Strategic Partnerships (Company Profiles from Official Sources)
• Applications in Regenerative Medicine, Tissue Engineering, and Drug Discovery
• Material Innovations: Nanomaterials, Bioinks, and Scaffold Design
• Regulatory Environment and Standardization Efforts (FDA, ISO, Industry Bodies)
• Challenges: Technical Barriers, Scalability, and Ethical Considerations
• Investment Landscape: Funding, M&A, and Startup Ecosystem
• Future Outlook: Emerging Opportunities and Disruptive Potential by 2030
• Sources & References

Executive Summary: Key Trends and Market Outlook (2025–2030)

Nanobioprinting technologies are poised for significant advancements and market expansion between 2025 and 2030, driven by breakthroughs in nanoscale biofabrication, increasing demand for personalized medicine, and the convergence of nanotechnology with 3D bioprinting. The sector is witnessing rapid innovation in the development of bioinks containing nanoparticles, nanofibers, and other nanomaterials, enabling the precise construction of tissues and organoids with enhanced biological functionality and structural fidelity.

Key industry players are accelerating research and commercialization efforts. CELLINK, a subsidiary of BICO Group, continues to lead in the development of advanced bioprinters and nanomaterial-based bioinks, supporting applications in tissue engineering and regenerative medicine. Organovo Holdings, Inc. is expanding its portfolio of 3D bioprinted human tissues, leveraging nanotechnology to improve cell viability and tissue maturation. Meanwhile, 3D Systems Corporation is investing in next-generation bioprinting platforms that integrate nanoscale precision for pharmaceutical testing and preclinical research.

Recent years have seen the emergence of collaborative initiatives between industry and academia to address technical challenges such as vascularization, cell differentiation, and scalability. For example, Thermo Fisher Scientific Inc. is partnering with research institutions to develop nanostructured scaffolds and reagents tailored for high-resolution bioprinting. These collaborations are expected to yield commercially viable solutions for complex tissue constructs by the late 2020s.

The regulatory landscape is also evolving, with agencies such as the U.S. Food and Drug Administration (FDA) engaging with industry stakeholders to establish guidelines for the clinical translation of nanobioprinted products. This is anticipated to streamline approval pathways and foster greater investment in the sector.

Looking ahead to 2030, the outlook for nanobioprinting technologies is robust. The integration of artificial intelligence and machine learning is expected to optimize print parameters and material selection, further enhancing reproducibility and scalability. Market adoption will be propelled by the growing need for patient-specific implants, drug screening models, and organ-on-chip systems. As manufacturing capabilities mature, cost barriers are likely to decrease, broadening access to advanced nanobioprinted solutions across healthcare and pharmaceutical industries.

• Accelerated R&D by leaders such as CELLINK, Organovo Holdings, Inc., and 3D Systems Corporation
• Expansion of nanomaterial-enabled bioinks and high-precision bioprinters
• Strengthening of industry-academic partnerships, e.g., with Thermo Fisher Scientific Inc.
• Regulatory progress supporting clinical and commercial adoption
• Broader application in personalized medicine, drug discovery, and regenerative therapies

Technology Landscape: Core Principles and Innovations in Nanobioprinting

Nanobioprinting technologies represent a convergence of nanotechnology, bioprinting, and advanced materials science, enabling the precise fabrication of biological structures at the nanoscale. As of 2025, the technology landscape is characterized by rapid innovation, with a focus on improving resolution, cell viability, and functional integration of printed tissues and devices. The core principle underlying nanobioprinting is the controlled deposition of bio-inks—comprising living cells, biomolecules, and nanomaterials—layer by layer to create complex, functional biological constructs.

Key technological advances in 2025 include the refinement of extrusion-based, inkjet, and laser-assisted bioprinting platforms, now adapted for nanoscale precision. Companies such as CELLINK (a BICO company) have introduced modular bioprinters capable of integrating nanomaterial-laden bio-inks, supporting applications from tissue engineering to drug screening. Organovo Holdings, Inc. continues to develop proprietary bioprinting platforms that leverage nanostructured scaffolds to enhance cell differentiation and tissue maturation, with a focus on liver and kidney models.

A significant innovation in the current landscape is the use of nanomaterials—such as gold nanoparticles, carbon nanotubes, and graphene derivatives—within bio-inks to impart electrical conductivity, mechanical strength, or bioactivity to printed constructs. Nanoscribe GmbH has advanced two-photon polymerization (2PP) systems, enabling the fabrication of intricate 3D micro- and nanostructures with sub-micron resolution, which are increasingly being adapted for bioprinting applications. These systems are instrumental in creating vascular networks and neural scaffolds with unprecedented precision.

Another trend is the integration of real-time monitoring and feedback systems, utilizing nanosensors embedded within printed tissues to assess cell health, differentiation, and microenvironmental conditions. This approach is being explored by research divisions within Thermo Fisher Scientific Inc., which supplies advanced reagents and analytical tools for nanobioprinting workflows.

Looking ahead to the next few years, the outlook for nanobioprinting technologies is marked by the anticipated commercialization of functional tissue patches, organ-on-chip systems, and personalized implants. Regulatory pathways are being clarified, and collaborations between industry leaders and academic institutions are accelerating the translation of laboratory advances into clinical and industrial settings. The convergence of artificial intelligence with nanobioprinting hardware is expected to further enhance design optimization and process control, paving the way for scalable, reproducible manufacturing of complex biological systems.

Market Size, Growth Drivers, and Forecasts Through 2030

The global market for nanobioprinting technologies is poised for significant expansion through 2030, driven by rapid advancements in bioprinting hardware, bio-ink formulations, and the increasing convergence of nanotechnology with tissue engineering. As of 2025, the sector is characterized by a surge in research and commercialization activities, particularly in the development of functional tissues, organoids, and precision drug testing platforms.

Key growth drivers include the rising demand for personalized medicine, the need for more accurate disease models, and the ongoing shortage of transplantable organs. Nanobioprinting, which integrates nanoscale materials and structures into bioprinting processes, enables the fabrication of tissues with enhanced biomimicry and cellular functionality. This capability is attracting investments from both established biotechnology firms and emerging startups.

Several leading companies are shaping the market landscape. CELLINK, a subsidiary of BICO Group, continues to expand its portfolio of bioprinters and nanomaterial-based bio-inks, targeting applications in regenerative medicine and pharmaceutical research. RegenHU is advancing multi-material and multi-scale bioprinting platforms, enabling the integration of nanostructures for improved cell guidance and tissue maturation. Organovo Holdings, Inc. remains a pioneer in the commercialization of 3D bioprinted human tissues, with ongoing efforts to incorporate nanoscale features for enhanced physiological relevance.

In 2025, the market is witnessing increased collaboration between technology providers and research institutions to accelerate the translation of nanobioprinted constructs from laboratory to clinical and industrial settings. For example, CELLINK has announced partnerships with leading academic centers to develop next-generation bio-inks containing nanoparticles for controlled drug delivery and improved cell signaling.

Looking ahead, the nanobioprinting market is expected to achieve a compound annual growth rate (CAGR) in the double digits through 2030, fueled by regulatory progress, expanding clinical trials, and the entry of new players. The Asia-Pacific region, particularly China and Japan, is anticipated to experience robust growth due to increased government funding and the establishment of dedicated bioprinting research hubs. Meanwhile, North America and Europe will maintain leadership in innovation and early adoption, supported by strong intellectual property portfolios and established biomedical industries.

• Expansion of product portfolios by companies such as CELLINK and RegenHU is expected to drive market penetration in both research and clinical segments.
• Emergence of standardized protocols and regulatory frameworks will facilitate the commercialization of nanobioprinted tissues and organoids.
• Strategic investments and mergers are likely as larger life sciences companies seek to enter or expand their presence in the nanobioprinting space.

Overall, the outlook for nanobioprinting technologies through 2030 is highly optimistic, with the potential to revolutionize regenerative medicine, drug discovery, and personalized healthcare.

Leading Players and Strategic Partnerships (Company Profiles from Official Sources)

The nanobioprinting technologies sector in 2025 is characterized by a dynamic landscape of established leaders, innovative startups, and strategic collaborations aimed at advancing the precision and scalability of bioprinting at the nanoscale. Several companies are at the forefront, leveraging proprietary technologies and forming partnerships to accelerate research, commercialization, and clinical translation.

One of the most prominent players is CELLINK, a subsidiary of BICO Group, which has expanded its portfolio to include high-resolution bioprinters capable of nano- and microscale fabrication. CELLINK’s collaborations with academic institutions and pharmaceutical companies have enabled the development of advanced tissue models and organ-on-a-chip systems, with a focus on reproducibility and scalability for drug discovery and regenerative medicine.

Another key innovator is Nanoscribe, a German company specializing in two-photon polymerization-based 3D printing. Nanoscribe’s Quantum X and Photonic Professional GT2 systems are widely used for fabricating intricate nanostructures, including scaffolds for cell culture and tissue engineering. In 2024 and 2025, Nanoscribe has announced partnerships with leading research institutes to co-develop next-generation bioinks and printing protocols tailored for cellular applications.

In the United States, Organovo Holdings, Inc. continues to be a pioneer in bioprinting, with a renewed focus on integrating nanoscale features into its tissue constructs. Organovo’s strategic alliances with pharmaceutical companies are aimed at producing more physiologically relevant models for preclinical testing, leveraging advances in nanomaterials and cell patterning.

Emerging players such as Aspect Biosystems are also making significant strides. Aspect’s microfluidic bioprinting platform, which allows for the precise deposition of cells and biomaterials, is being adapted for nanoscale applications through partnerships with materials science firms and academic labs. These collaborations are expected to yield breakthroughs in the fabrication of vascularized tissues and complex organoids over the next few years.

Strategic partnerships are a defining feature of the sector’s current trajectory. For example, CELLINK and Nanoscribe have both entered into agreements with major universities and biotechnology companies to co-develop bioinks and hardware optimized for nanobioprinting. These alliances are designed to bridge the gap between laboratory innovation and industrial-scale production, with a focus on regulatory compliance and clinical translation.

Looking ahead, the next few years are expected to see further consolidation and cross-sector collaboration, as companies seek to integrate advances in nanotechnology, biomaterials, and artificial intelligence. The leading players are well-positioned to drive the commercialization of nanobioprinting technologies, with a strong emphasis on reproducibility, scalability, and real-world biomedical applications.

Applications in Regenerative Medicine, Tissue Engineering, and Drug Discovery

Nanobioprinting technologies are rapidly transforming the landscape of regenerative medicine, tissue engineering, and drug discovery as of 2025. By integrating nanoscale precision with advanced bioprinting, these technologies enable the fabrication of complex, functional biological structures that closely mimic native tissues. This capability is driving significant advancements in both research and clinical applications.

In regenerative medicine, nanobioprinting is being leveraged to create patient-specific tissue grafts and organoids. Companies such as Organovo Holdings, Inc. have pioneered the development of 3D bioprinted human tissues for medical research and therapeutic applications. Their bioprinted liver and kidney tissues are being evaluated for use in disease modeling and potential transplantation. Similarly, CELLINK, a subsidiary of BICO Group, is actively developing nanobioprinting platforms that allow for the precise placement of cells and biomaterials at the microscale and nanoscale, supporting the creation of vascularized tissue constructs and skin grafts for wound healing.

In tissue engineering, nanobioprinting enables the fabrication of scaffolds with nanoscale features that promote cell adhesion, proliferation, and differentiation. 3D Systems has expanded its bioprinting portfolio to include technologies capable of producing highly detailed tissue scaffolds, which are being used in preclinical studies for bone and cartilage regeneration. The integration of nanomaterials, such as graphene and gold nanoparticles, into bioinks is further enhancing the mechanical and electrical properties of engineered tissues, opening new avenues for neural and cardiac tissue engineering.

Drug discovery is another area experiencing significant impact from nanobioprinting. The ability to bioprint organ-on-a-chip models with nanoscale resolution allows for more accurate simulation of human physiology and disease states. TissUse GmbH is at the forefront of this field, developing multi-organ microphysiological systems that facilitate high-throughput drug screening and toxicity testing. These platforms are expected to reduce reliance on animal models and accelerate the identification of promising drug candidates.

Looking ahead, the next few years are expected to see further integration of artificial intelligence and automation into nanobioprinting workflows, improving reproducibility and scalability. Regulatory agencies are also beginning to establish frameworks for the clinical translation of bioprinted tissues, which could pave the way for the first human trials of nanobioprinted implants by the late 2020s. As the technology matures, collaborations between industry leaders, such as Organovo Holdings, Inc., CELLINK, and 3D Systems, and academic institutions are expected to accelerate the commercialization and adoption of nanobioprinting in medicine and pharmaceutical research.

Material Innovations: Nanomaterials, Bioinks, and Scaffold Design

Nanobioprinting technologies are rapidly advancing, driven by innovations in nanomaterials, bioinks, and scaffold design. As of 2025, the integration of nanoscale materials into bioprinting processes is enabling the fabrication of highly functional, biomimetic tissues and structures with unprecedented precision. The convergence of nanotechnology and bioprinting is particularly evident in the development of next-generation bioinks and scaffolds, which are critical for tissue engineering, regenerative medicine, and pharmaceutical research.

A key trend in 2025 is the use of nanomaterials—such as carbon nanotubes, graphene, and nanocellulose—to enhance the mechanical, electrical, and biological properties of printed constructs. For example, nanocellulose-based bioinks are being explored for their biocompatibility and tunable rheological properties, supporting cell viability and proliferation. Companies like CELLINK (now part of BICO Group) are at the forefront, offering a range of nanomaterial-enhanced bioinks designed for specific tissue applications, including neural, cardiac, and musculoskeletal tissues.

In parallel, scaffold design is evolving through the incorporation of nanoscale features that mimic the extracellular matrix (ECM), promoting cell adhesion and differentiation. Advanced 3D bioprinters, such as those developed by Organovo and 3D Systems, are capable of depositing nanostructured materials with high spatial resolution, enabling the creation of complex tissue architectures. These platforms are increasingly used in preclinical drug testing and disease modeling, with several collaborations underway between bioprinting companies and pharmaceutical firms to accelerate the development of personalized medicine.

Another significant development is the emergence of hybrid bioinks that combine natural polymers (e.g., collagen, gelatin) with nanoparticles or nanofibers to achieve optimal printability and biological function. For instance, Allevi (a 3D Systems company) is actively developing composite bioinks that incorporate nanomaterials to enhance cell signaling and tissue maturation. These innovations are expected to improve the fidelity and scalability of bioprinted tissues, addressing longstanding challenges in vascularization and functional integration.

Looking ahead, the next few years are likely to see further breakthroughs in the customization of nanobioprinting materials, with a focus on smart bioinks that respond to environmental cues and dynamic scaffolds capable of guiding tissue regeneration. Regulatory pathways are also evolving, as industry leaders work with organizations such as the U.S. Food and Drug Administration to establish standards for nanomaterial-based bioprinted products. As these technologies mature, nanobioprinting is poised to play a transformative role in precision medicine, organ-on-chip systems, and ultimately, the fabrication of transplantable tissues and organs.

Regulatory Environment and Standardization Efforts (FDA, ISO, Industry Bodies)

The regulatory environment for nanobioprinting technologies is rapidly evolving as the field matures and moves closer to clinical and commercial applications. In 2025, regulatory agencies and standardization bodies are intensifying their focus on establishing clear frameworks to ensure the safety, efficacy, and quality of nanobioprinted products, particularly those intended for medical use.

The U.S. Food and Drug Administration (FDA) has been proactive in engaging with stakeholders in the bioprinting sector, including nanobioprinting, through its Center for Devices and Radiological Health (CDRH). The FDA’s Emerging Technology Program continues to provide a platform for early dialogue between developers and regulators, helping to clarify regulatory pathways for novel products such as bioprinted tissues and scaffolds. In 2024 and 2025, the FDA has increased its guidance activities, focusing on the characterization of nanomaterials, sterility assurance, and the validation of bioprinting processes. The agency is also collaborating with industry and academia to develop consensus standards for preclinical testing and quality control of nanobioprinted constructs.

On the international stage, the International Organization for Standardization (ISO) is advancing work on standards relevant to nanobioprinting. ISO Technical Committee 261 (Additive Manufacturing) and ISO/TC 229 (Nanotechnologies) are jointly addressing terminology, material specifications, and test methods for nanostructured bio-inks and printed constructs. In 2025, new draft standards are under review, aiming to harmonize requirements for biocompatibility, mechanical integrity, and reproducibility of nanobioprinted products. These efforts are expected to facilitate global regulatory acceptance and streamline cross-border commercialization.

Industry bodies such as the ASTM International are also playing a pivotal role. ASTM’s Committee F42 on Additive Manufacturing Technologies has established working groups focused on biofabrication and nanomaterials, developing guidelines for process validation, risk assessment, and post-processing of nanobioprinted devices. In 2025, ASTM is expected to release new standards addressing the unique challenges of integrating nanoscale features into bioprinted tissues, including surface characterization and functional testing.

Leading companies in the nanobioprinting sector, such as CELLINK (a BICO company), are actively participating in these regulatory and standardization initiatives. By collaborating with regulators and standards organizations, these companies aim to accelerate the translation of nanobioprinting innovations from the laboratory to the clinic, while ensuring compliance with evolving safety and quality requirements.

Looking ahead, the regulatory landscape for nanobioprinting technologies in 2025 and beyond is expected to become more defined, with increased alignment between national and international standards. This will likely reduce barriers to market entry and foster greater confidence among healthcare providers and patients in the safety and effectiveness of nanobioprinted medical products.

Challenges: Technical Barriers, Scalability, and Ethical Considerations

Nanobioprinting technologies, which integrate nanoscale precision with bioprinting, are rapidly advancing but face significant challenges as they move toward broader adoption in 2025 and the coming years. These challenges span technical barriers, scalability issues, and complex ethical considerations.

Technical Barriers: Achieving reliable nanoscale resolution in bioprinting remains a formidable technical hurdle. Current systems must precisely deposit bioinks containing living cells, growth factors, and nanomaterials without compromising cell viability or function. For example, companies like CELLINK and Organovo Holdings, Inc. are developing advanced printheads and bioinks, but maintaining cell health during the printing process—especially at the nanoscale—requires further innovation. Additionally, the integration of nanomaterials (such as nanoparticles or nanofibers) into bioinks can alter rheological properties, complicating print fidelity and reproducibility. Ensuring the structural and functional integrity of printed tissues, particularly for vascularized or multi-cellular constructs, is another ongoing technical challenge.

Scalability: Transitioning from laboratory-scale demonstrations to industrial-scale production is a major barrier for nanobioprinting. The throughput of current printers is limited, and scaling up without sacrificing resolution or biological function is non-trivial. Companies like 3D Systems and Stratasys Ltd. are investing in automation and multi-material printing platforms, but the complexity of nanobioprinted constructs—often requiring layer-by-layer assembly of heterogeneous materials—slows production rates. Moreover, the cost of high-precision equipment and specialized bioinks remains high, limiting accessibility for many research and clinical settings. Standardization of processes and materials is also lacking, which hinders reproducibility and regulatory approval.

Ethical Considerations: As nanobioprinting moves closer to clinical applications, ethical questions become increasingly prominent. The ability to fabricate functional tissues or organs raises concerns about patient consent, long-term safety, and equitable access. Regulatory bodies are beginning to address these issues, but frameworks are still evolving. For instance, the use of patient-derived cells and the potential for creating complex, personalized tissues necessitate robust data privacy and bioethical guidelines. Additionally, the incorporation of nanomaterials introduces uncertainties regarding biocompatibility and long-term effects, which must be thoroughly evaluated before widespread clinical use.

Looking ahead, overcoming these challenges will require coordinated efforts among technology developers, regulatory agencies, and the broader scientific community. Advances in printer design, bioink formulation, and process automation are expected, but addressing scalability and ethical concerns will be critical for the successful translation of nanobioprinting technologies from the lab to real-world applications.

Investment Landscape: Funding, M&A, and Startup Ecosystem

The investment landscape for nanobioprinting technologies in 2025 is characterized by a dynamic interplay of venture capital funding, strategic mergers and acquisitions (M&A), and a vibrant startup ecosystem. Nanobioprinting, which integrates nanoscale precision with bioprinting for applications in tissue engineering, regenerative medicine, and drug discovery, is attracting significant attention from both established industry players and emerging innovators.

In recent years, venture capital investment in nanobioprinting has accelerated, with funding rounds often exceeding tens of millions of dollars for promising startups. This trend is driven by the growing demand for advanced tissue models, organ-on-chip systems, and personalized medicine solutions. Notably, companies such as CELLINK (now part of BICO Group), a global leader in bioprinting, have continued to expand their nanobioprinting capabilities through both internal R&D and strategic acquisitions. CELLINK has acquired several complementary technology firms in recent years, strengthening its portfolio in high-resolution bioprinting and nanomaterial integration.

Another key player, Organovo Holdings, Inc., has maintained its focus on developing 3D bioprinted human tissues for medical research and therapeutic applications. The company’s ongoing collaborations with pharmaceutical and biotechnology firms underscore the commercial potential of nanobioprinting platforms in drug testing and disease modeling. Meanwhile, 3D Systems Corporation has expanded its healthcare division, investing in next-generation bioprinting technologies that incorporate nanoscale features to enhance cell viability and tissue function.

The startup ecosystem is particularly vibrant, with new entrants leveraging advances in nanomaterials, bioinks, and microfluidics. Startups such as Aspect Biosystems are developing proprietary microfluidic bioprinting platforms that enable precise control over cell placement and tissue architecture at the microscale and nanoscale. These innovations are attracting early-stage funding from both specialized life sciences investors and corporate venture arms of major healthcare companies.

M&A activity is expected to intensify over the next few years as larger biotechnology and medical device companies seek to acquire innovative nanobioprinting startups to bolster their R&D pipelines and accelerate commercialization. Strategic partnerships between academic institutions, startups, and established firms are also on the rise, facilitating technology transfer and scaling of nanobioprinting solutions.

Looking ahead, the investment outlook for nanobioprinting technologies remains robust. The convergence of nanotechnology and bioprinting is poised to unlock new therapeutic modalities and research tools, driving continued interest from investors and industry stakeholders. As regulatory pathways become clearer and clinical validation progresses, the sector is likely to witness further capital inflows, consolidation, and the emergence of new market leaders.

Future Outlook: Emerging Opportunities and Disruptive Potential by 2030

Nanobioprinting technologies are poised to redefine the landscape of biomedical engineering and regenerative medicine by 2030, with significant advancements expected in the next few years. As of 2025, the convergence of nanotechnology and bioprinting is enabling the fabrication of highly precise, functional biological structures at the cellular and subcellular levels. This capability is opening new avenues for tissue engineering, drug discovery, and personalized medicine.

Key industry players are accelerating the commercialization of nanobioprinting platforms. CELLINK, a subsidiary of BICO Group, continues to expand its portfolio of bioprinters and bioinks, focusing on nanoscale resolution and multi-material printing. Their recent collaborations with academic and clinical partners are aimed at developing vascularized tissues and organ-on-a-chip systems, which are critical for drug screening and disease modeling. Similarly, Organovo Holdings, Inc. is advancing its proprietary 3D bioprinting technology to create functional human tissues, with a growing emphasis on integrating nanomaterials to enhance cell viability and tissue maturation.

The integration of nanomaterials—such as nanoparticles, nanofibers, and nanocomposites—into bioinks is a major trend, enabling the creation of scaffolds that closely mimic the extracellular matrix. Companies like Nanoscribe GmbH & Co. KG are leveraging two-photon polymerization to achieve submicron precision in printing, which is essential for replicating the complex architecture of native tissues. This technology is expected to play a pivotal role in the fabrication of neural, vascular, and musculoskeletal tissues over the next five years.

Looking ahead, the disruptive potential of nanobioprinting extends beyond healthcare. The technology is being explored for applications in biosensing, environmental monitoring, and the development of smart materials. Industry consortia and regulatory bodies, such as the International Organization for Standardization (ISO), are actively working on standards to ensure the safety, reproducibility, and scalability of nanobioprinted products, which will be crucial for widespread adoption by 2030.

By the end of the decade, experts anticipate that nanobioprinting will enable the production of patient-specific implants, functional organoids for transplantation, and advanced in vitro models for precision medicine. The next few years will be marked by increased investment, cross-disciplinary collaborations, and the emergence of new startups, all contributing to the rapid evolution and commercialization of nanobioprinting technologies.

Sources & References

• CELLINK
• Organovo Holdings, Inc.
• 3D Systems Corporation
• Thermo Fisher Scientific Inc.
• Nanoscribe GmbH
• CELLINK
• Organovo Holdings, Inc.
• Aspect Biosystems
• TissUse GmbH
• Allevi
• International Organization for Standardization (ISO)
• ASTM International
• Stratasys Ltd.